OBJECTIVES: The study was carried out with the aim of evaluation of the adverse drug reaction profile of anti-snake venom serum (ASV) in a rural tertiary care hospital. METHODS: An observational study was conducted in SRTR Medical College, Ambajogai, Maharashtra, India. A total number of 296 indoor case papers of snake bite from February to September 2011 and June to August 2012 were retrieved from the record section and the antivenom reactions were assessed. In addition, basic epidemiological data and prescribing practices of ASV were also analyzed. RESULTS: Vasculotoxic snake bites were more common (50.61%) than neuroparalytic ones (22.56%). Mild envenomation was the commonest presentation. A total of 92 (56.10%) patients who received ASV suffered from antivenom reactions. The most common nature of reaction was chills, rigors (69.56%) followed by nausea and vomiting (34.8%). 10-15% patients suffered from moderate to severe reactions like hypotension and sudden respiratory arrest. We did not find any dose response relationship of ASV to risk of reactions (odds ratio 0.37). Intradermal sensitivity test was performed in about 72% cases. CONCLUSION: Our study showed a higher incidence of reactions to ASV at our institute.
OBJECTIVES: The study was carried out with the aim of evaluation of the adverse drug reaction profile of anti-snake venom serum (ASV) in a rural tertiary care hospital. METHODS: An observational study was conducted in SRTR Medical College, Ambajogai, Maharashtra, India. A total number of 296 indoor case papers of snake bite from February to September 2011 and June to August 2012 were retrieved from the record section and the antivenom reactions were assessed. In addition, basic epidemiological data and prescribing practices of ASV were also analyzed. RESULTS:Vasculotoxic snake bites were more common (50.61%) than neuroparalytic ones (22.56%). Mild envenomation was the commonest presentation. A total of 92 (56.10%) patients who received ASV suffered from antivenom reactions. The most common nature of reaction was chills, rigors (69.56%) followed by nausea and vomiting (34.8%). 10-15% patients suffered from moderate to severe reactions like hypotension and sudden respiratory arrest. We did not find any dose response relationship of ASV to risk of reactions (odds ratio 0.37). Intradermal sensitivity test was performed in about 72% cases. CONCLUSION: Our study showed a higher incidence of reactions to ASV at our institute.
Authors: Elena J Caron; Stephen R Manock; Jeffrey Maudlin; Jerome Koleski; R David G Theakston; David A Warrell; Roger D Smalligan Journal: Toxicon Date: 2009-06-09 Impact factor: 3.033
Authors: David J Williams; Simon D Jensen; Bill Nimorakiotakis; Reinhold Müller; Kenneth D Winkel Journal: Toxicon Date: 2006-12-02 Impact factor: 3.033
Authors: H Asita de Silva; Arunasalam Pathmeswaran; Channa D Ranasinha; Shaluka Jayamanne; Senarath B Samarakoon; Ariyasena Hittharage; Ranjith Kalupahana; G Asoka Ratnatilaka; Wimalasiri Uluwatthage; Jeffrey K Aronson; Jane M Armitage; David G Lalloo; H Janaka de Silva Journal: PLoS Med Date: 2011-05-10 Impact factor: 11.069
Authors: Chunfang Xie; Julien Slagboom; Laura-Oana Albulescu; Ben Bruyneel; Kristina B M Still; Freek J Vonk; Govert W Somsen; Nicholas R Casewell; Jeroen Kool Journal: Toxins (Basel) Date: 2020-01-16 Impact factor: 4.546